Radioactive iodine treatment of metastatic thyroid carcinoma with clinical thyrotoxicosis

Journal Article · Sun Dec 01 00:00:00 EST 1985 · Clin. Nucl. Med.; (United States)

DOI:https://doi.org/10.1097/00003072-198512000-00011· OSTI ID:5998001

Smith, R; Blum, C; Benua, R S; Fawwaz, R A

We present a case of well-differentiated follicular carcinoma of the thyroid with hyperfunctioning metastases and clinical thyrotoxicosis. The recommended I-131 treatment dose for patients with widespread bone metastases from thyroid carcinoma is 200 mCi. However, in a patient with hyperfunctioning metastatic tumor and increased radioiodine uptake, the treatment dose should be modified. Radiation dosimetry measurements performed on the patient in this study demonstrated that 132 mCi would be a safe therapeutic I-131 dose which would avoid injury to normal radiosensitive tissues. Consequently, she was given a 130-mCi therapeutic dose.

• Research Organization: Columbia Presbyterian Medical Center, New York, NY
• OSTI ID: 5998001
• Journal Information: Clin. Nucl. Med.; (United States), Vol. 12
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
CARCINOMAS
RADIOTHERAPY
THYROID
RADIATION DOSES
HYPERTHYROIDISM
IODINE 131
METASTASES
PATIENTS
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
BODY
DAYS LIVING RADIOISOTOPES
DISEASES
DOSES
ENDOCRINE DISEASES
ENDOCRINE GLANDS
GLANDS
INTERMEDIATE MASS NUCLEI
IODINE ISOTOPES
ISOTOPES
MEDICINE
NEOPLASMS
NUCLEAR MEDICINE
NUCLEI
ODD-EVEN NUCLEI
ORGANS
RADIOISOTOPES
RADIOLOGY
THERAPY
550604* - Medicine- Unsealed Radionuclides in Therapy- (1980-)
560161 - Radionuclide Effects
Kinetics
& Toxicology- Man